EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Differences in methylation profiles between long-term survivors and short-term survivors of IDH-wild-type glioblastoma

Matthijs van der Meulen iD, Ronald C Ramos, Mathew R Voisin, Vikas Patil, Qingxia Wei, Olivia Singh, Seth A Climans, Navya Kalidindi, Rosemarylin Or, Ken Aldape, Phedias Diamandis, David G Munoz und 2 weitere

Neuro-Oncology Advances · 01.01.2024 · 6 (1)

DOI: 10.1093/noajnl/vdae001 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Neuro-Oncology Advances, online erschienen am 12.01.2024. Verfasst von Matthijs van der Meulen und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Divisions of Neurology and Medical Oncology, Princess Margaret Cancer Centre, University of Toronto, Toronto, Ontario, Canada. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Pencer Brain Tumor Centre at University Health Network.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Patients with glioblastoma (GBM) have a median overall survival (OS) of approximately 16 months. However, approximately 5% of patients survive >5 years. This study examines the differences in methylation profiles between long-term survivors (>5 years, LTS) and short-term survivors (<1 year, STS) with isocitrate dehydrogenase (IDH)-wild-type GBMs.

Methods

In a multicenter retrospective analysis, we identified 25 LTS with a histologically confirmed GBM. They were age- and sex-matched to an STS. The methylation profiles of all 50 samples were analyzed with EPIC 850k, classified according to the DKFZ methylation classifier, and the methylation profiles of LTS versus STS were compared.

Results

After methylation profiling, 16/25 LTS and 23/25 STS were confirmed to be IDH-wild-type GBMs, all with +7/–10 signature. LTS had significantly increased O6-methylguanine methyltransferase (MGMT) promoter methylation and higher prevalence of FGFR3-TACC3 fusion (P = .03). STS were more likely to exhibit CDKN2A/B loss (P = .01) and higher frequency of NF1 (P = .02) mutation. There were no significant CpGs identified between LTS versus STS at an adjusted P-value of .05. Unadjusted analyses identified key pathways involved in both LTS and STS. The most common pathways were the Hippo signaling pathway and the Wnt pathway in LTS, and GPCR ligand binding and cell–cell signaling in STS.

Conclusions

A small group of patients with IDH-wild-type GBM survive more than 5 years. While there are few differences in the global methylation profiles of LTS compared to STS, our study highlights potential pathways involved in GBMs with a good or poor prognosis.

Schlagwörter

Stichwörter der Autor:innen

glioblastomalong-term survivorsmethylationpathway analysis

Autor:innen und Institutionen

  • Department of Medicine, Divisions of Neurology and Medical Oncology, Princess Margaret Cancer Centre, University of Toronto, Toronto, Ontario, Canada.
  • Department of Neurology, Medisch Spectrum Twente, Enschede, The Netherlands.
  • Division of Neurology, Department of Medicine, McMaster University, Hamilton, Ontario, Canada.
  • Division of Neurosurgery, Department of Surgery, University of Toronto, Toronto, Ontario, Canada.
  • MacFeeters Hamilton Centre for Neuro-Oncology Research, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
  • Department of Oncology, London Regional Cancer Program, London, Ontario, Canada.

ORCID-Profile: Matthijs van der Meulen, Gelareh Zadeh

Förderung

  • Pencer Brain Tumor Centre at University Health Network

Zitieren

APA

van der Meulen, M., Ramos, R. C., Voisin, M. R., Patil, V., Wei, Q., Singh, O., Climans, S. A., Kalidindi, N., Or, R., Aldape, K., Diamandis, P., Munoz, D. G., Zadeh, G., & Mason, W. P. (2024). Differences in methylation profiles between long-term survivors and short-term survivors of IDH-wild-type glioblastoma. Neuro-Oncology Advances, 6(1). https://doi.org/10.1093/noajnl/vdae001

Vancouver

van der Meulen M, Ramos RC, Voisin MR, Patil V, Wei Q, Singh O, et al. Differences in methylation profiles between long-term survivors and short-term survivors of IDH-wild-type glioblastoma. Neuro-Oncology Advances. 2024;6(1). doi:10.1093/noajnl/vdae001

BibTeX
@article{vanderMeulen2024,
  author = {van der Meulen, Matthijs and Ramos, Ronald C and Voisin, Mathew R and Patil, Vikas and Wei, Qingxia and Singh, Olivia and Climans, Seth A and Kalidindi, Navya and Or, Rosemarylin and Aldape, Ken and Diamandis, Phedias and Munoz, David G and Zadeh, Gelareh and Mason, Warren P},
  title = {Differences in methylation profiles between long-term survivors and short-term survivors of IDH-wild-type glioblastoma},
  journal = {Neuro-Oncology Advances},
  year = {2024},
  volume = {6},
  number = {1},
  doi = {10.1093/noajnl/vdae001}
}
Kostenlos starten →